Search Results - "Tokudome, Nahomi"

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients by Chu, David, Paoletti, Costanza, Gersch, Christina, VanDenBerg, Dustin A, Zabransky, Daniel J, Cochran, Rory L, Wong, Hong Yuen, Toro, Patricia Valda, Cidado, Justin, Croessmann, Sarah, Erlanger, Bracha, Cravero, Karen, Kyker-Snowman, Kelly, Button, Berry, Parsons, Heather A, Dalton, W Brian, Gillani, Riaz, Medford, Arielle, Aung, Kimberly, Tokudome, Nahomi, Chinnaiyan, Arul M, Schott, Anne, Robinson, Dan, Jacks, Karen S, Lauring, Josh, Hurley, Paula J, Hayes, Daniel F, Rae, James M, Park, Ben Ho

“…Mutations in the estrogen receptor (ER)α gene, ESR1, have been identified in breast cancer metastases after progression on endocrine therapies. Because of…”
Get full text

Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms by Paoletti, Costanza, Cani, Andi K, Larios, Jose M, Hovelson, Daniel H, Aung, Kimberly, Darga, Elizabeth P, Cannell, Emily M, Baratta, Paul J, Liu, Chia-Jen, Chu, David, Yazdani, Maryam, Blevins, Allen R, Sero, Valeria, Tokudome, Nahomi, Thomas, Dafydd G, Gersch, Christina, Schott, Anne F, Wu, Yi-Mi, Lonigro, Robert, Robinson, Dan R, Chinnaiyan, Arul M, Bischoff, Farideh Z, Johnson, Michael D, Park, Ben H, Hayes, Daniel F, Rae, James M, Tomlins, Scott A

“…Addressing drug resistance is a core challenge in cancer research, but the degree of heterogeneity in resistance mechanisms in cancer is unclear. In this…”
Get full text

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy by Tokudome, Nahomi, Koh, Yasuhiro, Akamatsu, Hiroaki, Fujimoto, Daichi, Okamoto, Isamu, Nakagawa, Kazuhiko, Hida, Toyoaki, Imamura, Fumio, Morita, Satoshi, Yamamoto, Nobuyuki

“…Epidermal growth factor receptor (EGFR)-sensitizing mutation, exon 19 deletion consists of several molecular variants. Influences of these variants on clinical…”
Get full text

Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients by Yagi, Satomi, Koh, Yasuhiro, Akamatsu, Hiroaki, Kanai, Kuninobu, Hayata, Atsushi, Tokudome, Nahomi, Akamatsu, Keiichiro, Endo, Katsuya, Nakamura, Seita, Higuchi, Masayuki, Kanbara, Hisashige, Nakanishi, Masanori, Ueda, Hiroki, Yamamoto, Nobuyuki

“…Circulating tumor cells (CTCs), defined as tumor cells circulating in the peripheral blood of patients with solid tumors, are relatively rare. Diagnosis using…”
Get full text

Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer by Nakamura, Seigo, Yagata, Hiroshi, Ohno, Shinji, Yamaguchi, Hiroshi, Iwata, Hiroji, Tsunoda, Nobuyuki, Ito, Yoshinori, Tokudome, Nahomi, Toi, Masakazu, Kuroi, Katsumasa, Suzuki, Eiji

“…Background Evaluating circulating tumor cells (CTCs) is one way to predict outcome and monitor treatment in patients with MBC. In this prospective study, we…”
Get full text

CD24, not CD47, negatively impacts upon response to PD‐1/L1 inhibitors in non–small‐cell lung cancer with PD‐L1 tumor proportion score < 50 by Ozawa, Yuichi, Harutani, Yuhei, Oyanagi, Jun, Akamatsu, Hiroaki, Murakami, Eriko, Shibaki, Ryota, Hayata, Atsushi, Sugimoto, Takeya, Tanaka, Masanori, Takakura, Toshiaki, Furuta, Katsuyuki, Okuda, Yuka, Sato, Kouichi, Teraoka, Shunsuke, Ueda, Hiroki, Tokudome, Nahomi, Kitamura, Yuka, Fukuoka, Junya, Nakanishi, Masanori, Koh, Yasuhiro, Yamamoto, Nobuyuki

“…CD24, a heavily glycosylated glycosylphosphatidylinositol–anchored surface protein, inhibits phagocytosis as potently as CD47. The relationship between such…”
Get full text

Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system by Ikeda, Mio, Koh, Yasuhiro, Teraoka, Shunsuke, Sato, Koichi, Kanai, Kuninobu, Hayata, Atsushi, Tokudome, Nahomi, Akamatsu, Hiroaki, Ozawa, Yuichi, Akamatsu, Keiichiro, Endo, Katsuya, Higuchi, Masayuki, Nakanishi, Masanori, Ueda, Hiroki, Yamamoto, Nobuyuki

“…Noninvasive diagnostics using circulating tumor cells (CTCs) are expected to be useful for decision making in precision cancer therapy. AXL, a receptor…”
Get full text

Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance by Paoletti, Costanza, Larios, Jose M., Muñiz, Maria C., Aung, Kimberly, Cannell, Emily M., Darga, Elizabeth P., Kidwell, Kelley M., Thomas, Dafydd G., Tokudome, Nahomi, Brown, Martha E., Connelly, Mark C., Chianese, David A., Schott, Anne F., Henry, N. Lynn, Rae, James M., Hayes, Daniel F.

“…Fulvestrant is a dose dependent selective estrogen receptor (ER) down-regulator (SERD) used in ER-positive metastatic breast cancer (MBC). Nearly all patients…”
Get full text

Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane by Okanami, Yuko, Ito, Yoshinori, Watanabe, Chie, Iijima, Kotaro, Iwase, Takuji, Tokudome, Nahomi, Takahashi, Shunji, Hatake, Kiyohiko

“…Background The purpose of this study was to determine the incidence of amenorrhea among breast cancer patients aged 40 years and younger following adjuvant…”
Get full text

Hepatitis B virus reactivation in adjuvant chemotherapy for breast cancer by Ide, Yoshimi, Ito, Yoshinori, Takahashi, Shunji, Tokudome, Nahomi, Kobayashi, Kokoro, Sugihara, Tsutomu, Hattori, Masaya, Yokoyama, Masahiro, Uchiyama, Akira, Inoue, Kazuaki, Sakurai, Norio, Hatake, Kiyohiko

“…Immunosuppressive therapy, such as chemotherapy or the use of corticosteroids, may stimulate reactivation of hepatitis B virus (HBV). Most of these episodes…”
Get full text

Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study by Sawaki, Masataka, Mukai, Hirofumi, Tokudome, Nahomi, Nakayama, Takahiro, Taira, Naruto, Mizuno, Toshiro, Yamamoto, Yutaka, Horio, Akiyo, Watanabe, Toru, Uemura, Yukari, Ohashi, Yasuo

“…Background For targeting anti-HER-2, trastuzumab-incorporated chemotherapy is the standard for HER-2-overexpressing breast cancer in adjuvant settings. But…”
Get full text

Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients by Tokudome, Nahomi, Ito, Yoshinori, Takahashi, Shunji, Kobayashi, Kokoro, Taira, Shinichiro, Tsutsumi, Chizuko, Oto, Masafumi, Oba, Masaru, Inoue, Kenichi, Kuwayama, Akiko, Masumura, Kyoko, Nakayama, Yoshie, Watanabe, Chie, Hatake, Kiyohiko

“…Background Circulating tumor cells (CTCs) are detected in peripheral blood of breast cancer patients, and they may play an important role as a prognostic and…”
Get full text

Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)] by Sawaki, Masataka, Tokudome, Nahomi, Mizuno, Toshiro, Nakayama, Takahiro, Taira, Naruto, Bando, Hiroko, Murakami, Shigeru, Yamamoto, Yutaka, Kashiwaba, Masahiro, Iwata, Hiroji, Uemura, Yukari, Ohashi, Yasuo

“…This trial is conducted to investigate the benefit of trastuzumab monotherapy compared with a combination therapy of trastuzumab and chemotherapy in women over…”
Get full text

Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways by Hatake, Kiyohiko, Tokudome, Nahomi, Ito, Yoshinori

“…Here we reviewed the recent progress of molecular targeting drugs, including trastuzumab, lapatinib, erlotinib and bevacituzumab. Fortunately, Her-2 positive…”
Get full text

Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes by Tanabe, Masahiko, Ito, Yoshinori, Tokudome, Nahomi, Sugihara, Tsutomu, Miura, Hiroyoshi, Takahashi, Shunji, Seto, Yasuyuki, Iwase, Takuji, Hatake, Kiyohiko

“…Background Most patients with breast cancer need anthracycline-based chemotherapy regimens in the adjuvant setting, and an increasing number of them receive…”
Get full text

Applicability of the Japanese equation for estimating glomerular filtration rate in patients with advanced-stage thoracic cancer by Kikuchi, Takashi, Akamatsu, Hiroaki, Mori, Keita, Tanaka, Ayaka, Kanai, Kuninobu, Hayata, Atsushi, Tokudome, Nahomi, Akamatsu, Keiichiro, Koh, Yasuhiro, Nakanishi, Masanori, Ueda, Hiroki, Yamamoto, Nobuyuki

“…Abstract Background The 24-hour creatinine clearance (24-h Ccr) and the Cockcroft-Gault equation (CG) are commonly used as markers of renal function in…”
Get full text

Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer by Ito, Yoshinori, Nagasaki, Koichi, Miki, Yoshio, Iwase, Takuji, Akiyama, Futoshi, Matsuura, Masaaki, Horii, Rie, Makita, Masujiro, Tokudome, Nahomi, Ushijima, Masaru, Yoshimoto, Masataka, Takahashi, Shunji, Noda, Tetsuo, Hatake, Kiyohiko

“…In patients with breast cancer, taxane as well as anthracycline play central roles in systemic chemotherapy. By evaluating the pathological response, we can…”
Get full text

A lower dose of docetaxel at 60 mg/m2 could be continued longer for controlling peripheral edema in patients with metastatic breast cancer by Hosonaga, Mari, Ito, Yoshinori, Tokudome, Nahomi, Takahashi, Shunji, Iwase, Takuji, Hatake, Kiyohiko

“…Background Docetaxel is a key drug for metastatic breast cancer (MBC). In patients with MBC, the treatment objective is durable response with minimum toxicity…”
Get full text

Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer? by Ito, Yoshinori, Tokudome, Nahomi, Sugihara, Tsutomu, Takahashi, Shunji, Hatake, Kiyohiko

“…ErbB/HER receptor or its signal transduction pathway is an attractive therapeutic target for breast cancer. Lapatinib, an orally administered dual inhibitor of…”
Get full text

High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer by Sawaki, Masataka, Ito, Yoshinori, Akiyama, Futoshi, Tokudome, Nahomi, Horii, Rie, Mizunuma, Nobuyuki, Takahashi, Shunji, Horikoshi, Noboru, Imai, Tsuneo, Nakao, Akimasa, Kasumi, Fujio, Sakamoto, Goi, Hatake, Kiyohiko

“…Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. Although the survival of patients with IBC has been greatly improved by…”
Get full text